YolTech Therapeutics’ Post

The RNA Based Therapeutics Breakthrough : How it's Changing the Game for Patients 𝐈𝐧 𝐃𝐞𝐭𝐚𝐢𝐥𝐬 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 : https://lnkd.in/g8J4PSPF The RNA-based therapeutics market is on a meteoric rise, driving innovations in how we tackle some of the most complex diseases. With technologies like RNA interference (RNAi), antisense oligonucleotides (ASOs), and mRNA therapies leading the charge, the possibilities seem endless. From mRNA vaccines rapidly developed for COVID-19 to gene silencing therapies targeting rare genetic disorders, the RNA revolution is reshaping drug development. Pharma companies are heavily investing in these platforms, with the global RNA therapeutics market projected to surpass $10 billion by 2027. Key drivers include: Advancements in delivery systems: Overcoming challenges in safely delivering RNA molecules to specific cells. Growing applications in oncology: RNA therapies are being tailored to target and destroy cancer cells. Personalized medicine: The ability to develop treatments based on individual genetic profiles. With ongoing clinical trials and regulatory approvals accelerating, RNA-based therapies are set to transform the future of healthcare. #RNATherapeutics #Biotech #PharmaInnovation #GeneTherapy #FutureOfMedicine

🌟 The RNA-Based Therapeutics Breakthrough: Transforming Patient Care🌟 🔬 The RNA-based therapeutics market is experiencing a meteoric rise, driving innovations in how we tackle some of the most complex diseases. With technologies like RNA interference (RNAi), antisense oligonucleotides (ASOs), and mRNA therapies leading the charge, the possibilities seem endless. 📈 Key Highlights: - mRNA Vaccines: Rapidly developed for COVID-19, showcasing the potential of RNA-based solutions in addressing global health crises. - Gene Silencing Therapies: Targeting rare genetic disorders, offering new hope for patients with previously untreatable conditions. - Market Growth: The global RNA therapeutics market is projected to surpass $10 billion by 2027, driven by significant investments from pharmaceutical companies⁸. 🔍 Key Drivers: - Advancements in Delivery Systems: Overcoming challenges in safely delivering RNA molecules to specific cells, enhancing the efficacy and safety of these therapies. - Innovative Platforms: Continuous development of new RNA-based platforms, expanding the scope of treatable conditions. - Personalized Medicine:The ability to develop treatments based on individual genetic profiles, paving the way for more tailored and effective therapies. 💡 Why It Matters: The RNA revolution is reshaping drug development, providing more precise and effective treatments. This breakthrough is not just a scientific achievement but a beacon of hope for millions of patients worldwide. #RNATherapeutics #Biotechnology #GeneTherapy #mRNAVaccines #PharmaInnovation #HealthcareRevolution #MedicalLaboratoryTechnology #Microbiology #Phlebotomy #LaboratoryTesting #DiagnosticTesting #HealthcareProfessional #MedicalTesting #ClinicalLaboratory #BiomedicalScience #HealthcareIndustry #MedicalScience #LaboratoryMedicine #ClinicalMicrobiology #InfectionControl #PhlebotomyTechnician #MedicalLabTechnician #MicrobiologyLab #ClinicalLab #HealthcareCareer #MedicalCareer #ScienceCareer #COVID19Testing #Virology #Bacteriology #Parasitology #MolecularDiagnosis #GeneticTesting #Cytology #Histopathology #Immunology #Serology

📢 AusBiotech welcomes today’s release of Australia’s RNA Blueprint, building on the existing Medical Science Co-investment Plan. There’s no doubt that advanced therapies developed using RNA-based technologies are at the forefront of Australia’s therapeutic revolution in medicine. Immunogenicity, capacity for rapid development and safe administration, when compared to conventional platforms such as small molecules and proteins, mean they hold great promise for new therapies and new standards of care. We’re proud that a number of our members are already engaging in home grown RNA research and development right here in Australia.     We are also pleased to see Australia’s Cell & Gene Catalyst, a joint venture between AusBiotech and Medicines Australia, recognised for its potential as a strategic partner to bring the ecosystem together, and collaborate for impact by enabling connection and collaboration at the national level. The Catalyst aims to accelerate the development, manufacture and commercialisation of cell and gene therapies, including RNA, to foster a prosperous cell and gene industry in Australia.   We look forward to working with Government to bring the Blueprint into action. Read more here: https://lnkd.in/g-xQxC2r   The Hon. Ed Husic MP, Minister for Industry and Science, the Hon. Mark Butler MP, Minister for Health and Aged Care, Cell Therapies Pty Ltd CSL Behring, Novartis, Pfizer, Roche, Therapeutic Innovation Australia #MinisterHusic #MinisterButler #RNA #RNABlueprint #AusBiotech #MedicinesAustralia #AustraliasCellandGeneCatalyst

It's an exciting time to be involved in the RNA field, especially with the backing and direction provided by Australia's RNA Blueprint. This initiative highlights our ribonucleic acid (RNA) potential and outlines the steps that governments, academia, and industry can take to foster the growth of Australia's #RNA sector.   #oligonucleotides #biotechnology

🚀 AI Drug Discovery Weekly Wrap-Up 🚀 Here are the latest breakthroughs and major moves in AI-powered drug discovery this week: 💡 Terray Therapeutics raises $120M Series B: Terray is leveraging generative AI to transform small molecule drug development, advancing immunology programs into the clinic and partnering with Bristol Myers Squibb & Calico.   Source: https://lnkd.in/dG_8YZZZ  🧬 Dotmatics launches Geneious Luma platform: Dotmatics is rolling out a powerful R&D software to streamline antibody and protein engineering, accelerating discovery in fields like CRISPR, CAR-T, and vaccines.   Source: https://lnkd.in/gepFCGgM  🧑🔬 GSK partners with Cambridge on immune diseases: A $65M collaboration will combine patient data, AI, and machine learning to discover better treatments for hard-to-treat kidney and lung diseases.   Source: https://lnkd.in/gGBKJBye    🧠Roche expands Dyno Therapeutics partnership: With a new $1B deal, Roche is doubling down on AI-optimized gene therapies for neurological disorders using Dyno’s AAV vectors.   Source: https://lnkd.in/eD46iDx6  #AIDDD #aidrivendrugdiscovery #aidrugdiscovery

Great insights

The RNA space has seen a dramatic increase in investments ($228B USD in 2021 compared to $3B USD in 2014), platforms development and the number of drug programs. The major drivers are the increase in the frequency of approvals in this class, the rise of CRISPR gene editing, and the success of the COVID-19 mRNA vaccines. The current article discusses common frameworks for developing RNA drug platforms, the potential of RNA-based therapeutics to transform medicine, and the key challenges facing the wide adoption of RNA technologies in different therapeutic areas. 𝐊𝐞𝐲 𝐩𝐨𝐢𝐧𝐭𝐬: - RNA is well-suited as a drug platform technology due to its target-to-target adaptability and modular design structure, however, its ADME profile is fundamentally limited and more efforts are need to broaden its applicability. - The wide use of the term "RNA drug platform" and the diverse examples of RNA platform technologies has led to ambiguity around the true definition of a powerful, mature platform. Key strategies for developing RNA platforms include layering technologies with rigorous evaluation and iterative optimization, addressing common biases that impact decision-making, and identifying gaps in knowledge especially in discrepancies between preclinical evaluation and clinical outcomes. Link: https://lnkd.in/dmpKw_MN #RNAtherapeutics #siRNA #ASO #Oligonucleotide #Platformtechnology

How you do #preclinical #immunogenicity risk assessment is an important factor in #Biologics R&D, especially when translating to the clinic. The Antibody Society seminar below will help you consider one viable option. #Immunogenicity #Immunoassays #DrugDevelopment #DrugDiscovery #Biopharma #Oncology #Research #TranslationalMedicine #PatientCentric

Save the date for a great webinar!

⏳ 𝑻𝒉𝒆 𝑬𝒗𝒐𝒍𝒖𝒕𝒊𝒐𝒏 𝒐𝒇 𝑳𝑵𝑷𝒔 𝒊𝒏 𝑫𝒓𝒖𝒈 𝑫𝒆𝒍𝒊𝒗𝒆𝒓𝒚 LNPs have come a long way since their inception! In 1965 Bangham et al. first described lipid liquid crystals emphasizing the different behaviors of cations and anions and how surface charge impacts their properties. Fast forward to the late '90s and early 2000s, LNPs started gaining attention as delivery system for small molecule chemotherapy drugs such as doxorubicin, irinotecan and cytarabine - enhancing their stability and bioavailability. Today, LNPs are widely used to deliver nucleic acid-based therapeutics for various diseases including cancer, protein replacement therapies, and gene editing through CRISPR-Cas9 technology. Their potential became globally recognized during the COVID-19 pandemic, with the mRNA vaccines mRNA-1273 and BNT162b2 developed by Moderna and Pfizer-BioNTech respectively. The future of LNPs looks incredibly promising with novel-formulations and engineering efforts. LNPs can now achieve successful extrahepatic delivery after i.v administration and targeted specific cell types with antibody conjugation on their surface. Exciting times are ahead of us for novel, effective and targeted nanomedicine strategies ! 🔬 #Biotechnology #Nanomedicine #mRNA #DrugDelivery #CRISPR #LipidNanoparticles #GeneTherapy #CancerTreatment #COVID19 #LNPs #InnovativeScience #NextGenMedicine #HealthTech #FutureOfMedicine #BiomedicalResearch